ValiRx (LSE:VAL) Operating Cash Flow per Share : £-0.01 (TTM As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx Operating Cash Flow per Share?

ValiRx's operating cash flow per share for the six months ended in Dec. 2024 was £-0.01. ValiRx's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was £-0.01.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 14.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 38.10% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 56.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for ValiRx's Operating Cash Flow per Share or its related term are showing as below:

LSE:VAL' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 9.1 Med: 50.5 Max: 72.6
Current: 14.2

During the past 13 years, ValiRx's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.60% per year. The lowest was 9.10% per year. And the median was 50.50% per year.

LSE:VAL's 3-Year OCF Growth Rate is ranked better than
55.23% of 1215 companies
in the Biotechnology industry
Industry Median: 9.4 vs LSE:VAL: 14.20

ValiRx Operating Cash Flow per Share Historical Data

The historical data trend for ValiRx's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Operating Cash Flow per Share Chart

ValiRx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.05

-0.02

-0.01

ValiRx Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.01	-0.01

Competitive Comparison of ValiRx's Operating Cash Flow per Share

For the Biotechnology subindustry, ValiRx's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ValiRx's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ValiRx's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

ValiRx Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

ValiRx's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-1.585	/	131.774
	=	-0.01

ValiRx's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Dec. 2024 )	=	Cash Flow from Operations (Q: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
	=	-0.694	/	132.355
	=	-0.01

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01

ValiRx Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of ValiRx's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.